Financial Performance - Revenue for the six months ended June 30, 2025, was $1,652,000, a decrease of 55.4% compared to $3,704,000 for the same period in 2024[11]. - Gross profit for the same period was $1,214,000, down 58.9% from $2,954,000 year-over-year[11]. - The net loss for the period was $(7,792,000), a slight improvement of 1.9% compared to $(7,943,000) in the previous year[11]. - Revenue for the six months ended June 30, 2025, was approximately $1.7 million, a decrease of about 55.4% compared to $3.7 million for the same period in 2024[77]. - Gross profit for the same period was approximately $1.2 million, down about 58.9% from $3.0 million in the previous year, resulting in a gross margin of approximately 73.5%[79]. - Other income and gains increased to approximately $4.5 million, up about $1.1 million from $3.4 million in the previous year, primarily due to increased government subsidies[80]. - Research and development costs decreased to approximately $4.5 million, down about 31.4% from $6.5 million in the previous year, due to a focus on core product development[84]. - Cash and bank balances totaled approximately $130.8 million as of June 30, 2025, a decrease of about $8.5 million from $139.3 million at the end of 2024[87]. - The capital debt ratio as of June 30, 2025, was 0.03%, a decrease from 0.19% at the end of 2024[90]. - Sales and distribution expenses were approximately $3.3 million, a decrease of about 11.9% compared to the previous year[81]. - The adjusted net loss for the six months ended June 30, 2025, was $6,956,000, compared to $7,832,000 for the same period in 2024, reflecting a decrease of approximately 11.1%[97]. - Total employee costs for the reporting period were approximately $6.01 million, down from $7.86 million in the same period of 2024, indicating a reduction of about 23.5%[103]. - The company reported a net loss of $7,792,000 for the six months ended June 30, 2025, slightly improved from a net loss of $7,943,000 in the same period of 2024[97]. Product Development and Innovation - The company’s core product, BroncAblate®智衡®, received approval from the National Medical Products Administration (NMPA) for market launch in China, marking a significant innovation in lung cancer treatment[12]. - As of July 2025, BroncAblate®智衡® has been clinically applied in multiple top medical centers across the country, demonstrating significant clinical efficacy[13]. - InterVapor® has been trialed in over 200 hospitals in China, with more than 500 clinical applications reported, receiving positive feedback from both doctors and patients[14]. - The company is advancing its clinical trials for the TLD ablation system, with 109 subjects enrolled as of June 30, 2025, showing general improvement in patient clinical performance[17]. - The company is actively promoting innovative products in the respiratory intervention field, with a focus on commercializing and expanding clinical applications[16]. - The lung imaging processing software BroncQCT® received approval from the Zhejiang Provincial Drug Administration for market entry in China in March 2025, significantly enhancing doctors' efficiency in interpreting lung CT images[18]. - The LungPro® augmented reality optical lung navigation system was showcased at the 5th International Sublobar Conference and Bronchoscopic Ablation Summit in Paris, highlighting its clinical advancements and strong feedback from experts[20]. - The company established a comprehensive interventional respiratory disease treatment platform, integrating navigation, diagnosis, and treatment, addressing unmet clinical needs in the rapidly growing interventional pulmonology market[24]. - The company showcased its one-stop respiratory intervention innovation solution at the 2025 CMEF in Shanghai, covering the entire process from precise positioning to effective treatment[21]. - The company is committed to global strategic expansion, actively promoting its products and technologies in international markets[20]. Market Presence and Regulatory Approvals - As of June 30, 2025, the company holds 69 overseas registration certificates, including 4 CE certificates and 7 FDA certificates, indicating successful market access efforts[23]. - The company introduced the BroncAblate®智衡® lung radiofrequency ablation system at multiple academic forums, receiving high praise for its clinical value in minimally invasive lung treatment[23]. - The company is focusing on the commercialization of interventional treatment products, with ongoing clinical trials and product development aimed at filling domestic market gaps[63]. - The respiratory intervention market is evolving towards precision treatment, necessitating a repositioning of navigation products to enhance their clinical value[63]. - The company aims to expand its market space and accelerate the development of more product pipelines to support sustainable growth and value creation[71]. - The company has received government subsidies totaling $1.7 million during the reporting period, compared to $0.1 million as of June 30, 2024[72]. - The company is actively promoting the inclusion of innovative products in China's medical insurance, with InterVapor® already covered in some provinces[69]. Clinical Trials and Research - The company is actively conducting post-market clinical studies for InterVapor® across over 30 hospitals in China, aiming to gather high-quality evidence for COPD treatment[38]. - The TLD radiofrequency ablation energy system, developed in collaboration with Sichuan University, has initiated a clinical trial involving 189 moderate to severe COPD patients across over 20 centers, with more than 100 participants enrolled as of June 30, 2025[39]. - The BTVA technique, associated with the InterVapor® system, has been included in the GOLD guidelines for COPD treatment for seven consecutive years, highlighting its significance in improving lung function and quality of life for patients[36]. - The TLD system's clinical trial is expected to complete all follow-ups by 2026, with data release planned post-trial completion[39]. Corporate Governance and Compliance - The company has established compliance policies to ensure adherence to applicable laws and regulations, with no significant non-compliance events reported during the period[141]. - The company has adopted corporate governance practices based on the principles outlined in the Corporate Governance Code, ensuring compliance with applicable provisions[142]. - The company will continue to review and monitor its corporate governance practices to maintain high standards[144]. Shareholder Information and Equity Plans - The company did not recommend the payment of an interim dividend for the reporting period, consistent with the previous year[98]. - The company has adopted two equity incentive plans: a stock option plan and a restricted share unit plan[114]. - The total number of securities available for issuance under the stock option plan is 4,096,960 shares, approximately 0.78% of the total issued shares[115]. - The company has a stock option plan that allows for the granting of options to eligible participants, including senior executives and employees, with a maximum allocation of 1% of issued shares[119]. - The company has a total of 2,658,588 shares in BRS Biomedical Limited, with 2,160,000 shares attributed to Mr. Zi under a restricted share unit plan[117]. - The company has not granted any rewards under the Restricted Share Unit Plan during the reporting period, with the number of available rewards remaining at 51,922,566 shares[123].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | ...

堃博医疗-B(02216)发布截至2025年6月30日止6个月中期业绩，集团收入165.2万美元，同比减少55.4%; 净亏损779.2万美元，同比收窄1.9%;毛利121.4万美元，同比减少58.9%。 ...

Core Viewpoint - Kubo Medical-B (02216) reported a significant decline in revenue for the six months ending June 30, 2025, indicating challenges in the business environment [1] Financial Performance - The company's revenue was $1.652 million, representing a year-on-year decrease of 55.4% [1] - Net loss for the period was $7.792 million, which is a slight improvement of 1.9% compared to the previous year [1] - Gross profit stood at $1.214 million, down 58.9% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Broncus Holding Corporation 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 堃博醫療控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公 司及其附屬公司（統稱「本集團」或「我們」）截至2025年6月30日止六個月（「報告 期」）之未經審核綜合中期業績，連同截至2024年6月30日止六個月之未經審核比 較數字。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至 | 截至 | | | | 2025年 | 2024年 | | | | 6月30日 | 6月30日 | | | | 止六個月 | 止六個月 | 同比變動 | | | 千美元 | 千美元 | | | 收入 | 1,652 | 3,704 | -55.4% | | 毛利 | 1,214 | 2,954 | -58.9% | | 期內虧損 | (7,79 ...

智通财经APP获悉，中国生物制药(01177)、驴迹科技(01745)、立高控股(08472)、堃博医疗-B(02216)于 2025年8月21日进行了最新股东权益披露。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 中国生物制药 | 谢炘 | 好仓 | 3.59 亿股 | 3.60 亿股 | 1.92%(最新) | | (01177) | | | | | 1.91%(前次) | | 驴迹科技(01745) | Lu Jia Technology | 好仓 | 8.41 亿股 | 8.38 亿股 | 33.11%(最新) | | | Holdings Limited | | | | 49.82%(前次) | | 立高控股(08472) | Yongxin Global | 好仓 | 1270.20 万股 | 970.20 万股 | 8.42%(最新) | | | Investment Limited | | | | 11.03%(前次) | | 堃博医疗 | Computershare Ho ...

格隆汇8月18日丨堃博医疗-B(02216.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 香港，2025年8月18日 （股份代號：2216） 董事會會議召開日期 堃博醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，董事 會會議將於2025年8月28日（星期四）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2025年6月30日止六個月之未經審核中期業績及其刊發。 承董事會命 堃博醫療控股有限公司 董事長 徐宏 Broncus Holding Corporation 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會包括執行董事徐宏先生、非執行董事張奧先生及鄺豔紅女 士，以及獨立非執行董事甘博文博士、黃依倩女士及David Scott Lim醫生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Broncus Holding Corporation 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2216） 根據受限制股份單位計劃授出獎勵 本公告乃由本公司根據《上市規則》第17.06A、17.06B及17.06C條作出。本公司 宣佈，於2025年7月28日，本公司根據受限制股份單位計劃的條款向7名承授人授 出352,683份獎勵（與相關股份數目相同，及相當於本公告日期已發行股份總數約 0.07%），惟須待獲接納後方可作實。 授出獎勵的詳情 所有承授人均為本集團僱員及均為獨立第三方。 授出獎勵旨在獎勵承授人的表現及對本集團作出的貢獻，通過擁有股份、股息及 其他股份分派及╱或股份增值，使承授人的利益與本集團的利益保持一致，並鼓 勵及挽留承授人為本集團的長期增長及利潤作出貢獻。 可用於未來授出的股份數目 獲授獎勵的購買價 ： 零 股份於授出日期的 ： 每股股份2.68港元 收市 ...